News

GRObio CEO, Dan Mandell, interviews professor George Church about the Genomically Recoded Organisms (GRO) platform that Dan spun out of his lab, asks him what technologies he is working on...

Ryan Cross interviewed our CEO, Dan Mandell, PhD, about how the Company’s GRO platform expands the limited amino acid alphabet that nature uses to make proteins, and how our Series...

Biotech TV host Brad Loncar visited GRObio’s office in Cambridge and had a discussion with GRObio CEO Dan Mandell, PhD about the Company’s recent Series B financing. In the interview,...

James Waldron reported on how GRObio’s $60.3 million Series B financing allows the Company to acquire clinical efficacy for its lead program in chronic refractory gout, and how our approach...

Hannah Green interviewed our CEO, Dan Mandell, PhD, about how GRObio’s ProGly-NSAAs prevent immune reactions that render many therapies ineffective, and how resolving this critical limitation is key to advancing...

Frank Vinluan interviewed our CEO, Dan Mandell, PhD, on GRO Biosciences’ platform for engineering therapeutic proteins without the immune reactions that often impair safety and efficacy, and how the Company’s...

LISTEN TO THE PODCAST In this episode, Biorasi CEO Chris O’Brien hosted scientist and entrepreneur Daniel J. Mandell, Ph.D. to discuss how his creativity and imagination led him on a...

Read Article proto.life: Scientists have created an organism that defies the rules of biology by using nonstandard amino acids. And you probably have some questions. Katia Tarasava, PhD, interviewed our...